Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Gene activation

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    101 result(s) found for: Gene activation. Displaying page 1 of 6.
    1  2  3  4  5  6  Next»
    EudraCT Number: 2008-005538-59 Sponsor Protocol Number: 22-09-2008 Start Date*: 2009-02-18
    Sponsor Name:ZonMw
    Full Title: Impulsivity, a risk factor in relapse to substance use disorder: investigating neural substrates before and after pharmacological challenges
    Medical condition: Alcohol dependence Cocaine dependence
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-004292-69 Sponsor Protocol Number: MEFV01 Start Date*: 2016-01-12
    Sponsor Name:UZ Leuven
    Full Title: Anakinra (Kineret®) for a hereditary autoinflammatory disease with MEFV mutation and inflammasome activation.
    Medical condition: hereditary autoinflammatory disease with MEFV mutation and inflammasome activation
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2012-003750-89 Sponsor Protocol Number: KKS-186 Start Date*: 2013-02-14
    Sponsor Name:Philipps-University Marburg
    Full Title: A placebo-controlled, double blind, randomised trial with crossover-design investigating the effect of oxytocin nasal spray on neuronal processes of empathy
    Medical condition: high-functioning autism spectrum disorders: autistic disorder (F84.0), Asperger syndrome (F84.5), atypical autism (F 84.1)
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004852 10021737 Infantile autism LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-002094-22 Sponsor Protocol Number: 2013MM002B Start Date*: 2013-08-29
    Sponsor Name:Royal Brompton and Harefield NHS Foundation Trust (RB&HFT)
    Full Title: Comparison of ultra-low-dose Oral versus Transdermal Hormone Therapy on coagulation activation and metabolic risk factors for Cardiovascular Disease
    Medical condition: The effect of oestrogen replacement therapy taken either orally or transdermally and observing any likely benefit of both these therapies on the risks Venous thromobembolic events and cardiovascul...
    Disease: Version SOC Term Classification Code Term Level
    16.1 10038604 - Reproductive system and breast disorders 10027309 Menopause and related conditions HLGT
    Population Age: Adults Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2020-002672-12 Sponsor Protocol Number: 73807 Start Date*: 2020-12-11
    Sponsor Name:Erasmus Medical Center
    Full Title: Frontotemporal dementia Imaging of Neuroinflammation, Degeneration and Microglia-Related Effects
    Medical condition: Frontotemporal dementia (FTD), including symptomatic patients and presymptomatic individuals with genetic mutations predisposing to FTD at a later stage in life.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-002909-25 Sponsor Protocol Number: 74310 Start Date*: 2020-10-21
    Sponsor Name:Amsterdam University Medical Centers
    Full Title: Blood-borne assessment of stromal activation in esophageal adenocarcinoma to guide tocilizumab therapy: a randomized phase II proof-of-concept study
    Medical condition: oesophageal adenocarcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-000677-23 Sponsor Protocol Number: CLCL161A2201 Start Date*: 2012-10-24
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Phase II, multi-center, open-label, neoadjuvant, randomized study of weekly paclitaxel with or without LCL161 in patients with triple negative breast cancer
    Medical condition: Triple negative breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) ES (Completed) IE (Completed) IT (Completed) BE (Completed) CZ (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2022-001484-27 Sponsor Protocol Number: NL67672.091.18 Start Date*: 2023-01-24
    Sponsor Name:radboudumc
    Full Title: B cell Activation in Sjögren's Syndrome, Cutaneous Lupus Erythematodus and Systemic Sclerosis Tissues Analysis 2
    Medical condition: Systemic Sclerosis Sjögren's Syndrome Cutaneous Lupus Erythematodus
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-002879-14 Sponsor Protocol Number: BioVacSafe-Boostrix® Start Date*: 2015-07-30
    Sponsor Name:Ghent University Hospital
    Full Title: BioVacSafe-Boostrix®: een klinische studie om een reeks gegevens te regenereren die kenmerkend zijn voor klinische gebeurtenissen, fysiologische reacties en aangeboren en adaptieve immuunreacties v...
    Medical condition: vaccin against diphtheria, tetanus and pertussis.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004865 10046859 Vaccination LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-003543-35 Sponsor Protocol Number: BioVacSafe–FluadTM Start Date*: 2014-09-23
    Sponsor Name:Ghent University Hospital
    Full Title: A clinical study to generate a set of data characterising clinical events, physiological responses, and innate and adaptive immune responses following a single intramuscular immunisation with Fluad...
    Medical condition: vaccin against influenza
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004865 10046859 Vaccination LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2019-001806-40 Sponsor Protocol Number: STATLiver2019 Start Date*: 2019-09-03
    Sponsor Name:Afsnit 360, Gastroenheden
    Full Title: Statins for prevention of disease progression and hospitalization in Liver Cirrhosis: A multi-center, randomized, double blind, placebo-controlled trial. The STATLiver Trial.
    Medical condition: Cirrhosis of the liver
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004871 10024667 Liver cirrhosis LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-002991-42 Sponsor Protocol Number: HCV-13-01 Start Date*: 2013-12-19
    Sponsor Name:Foundation for Liver Research
    Full Title: Effect of ASV and DCV therapy on the quality of immune status in chronic HCV patients Investigator initiated research proposal nr. AI447-108
    Medical condition: Chronic hepatitis C
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-001856-51 Sponsor Protocol Number: 12.007 Start Date*: 2014-08-26
    Sponsor Name:Aleksander Krag
    Full Title: Anti-fibrotic and molecular aspects of rifaximin in alcoholic liver disease: A randomized placebo controlled clinical trial
    Medical condition: Liver fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004871 10016648 Fibrosis liver LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2020-001461-36 Sponsor Protocol Number: CT-AMT-130-02 Start Date*: 2021-06-30
    Sponsor Name:uniQure biopharma B.V.
    Full Title: A Phase Ib/II Randomised, Double-Blind Study to Explore Safety, Tolerability, and Efficacy Signals of Multiple Doses of Striatally-Administered rAAV5-miHTT Total Huntingtin Gene (HTT) Lowering Ther...
    Medical condition: Huntington Disease
    Disease: Version SOC Term Classification Code Term Level
    27.1 10010331 - Congenital, familial and genetic disorders 10070668 Huntington's disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: PL (Trial now transitioned) DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-000418-75 Sponsor Protocol Number: TV5600-CNS-20007 Start Date*: 2014-11-18
    Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc.
    Full Title: A Multicenter, Multinational, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0 and 1.5 mg/day) as Treatment in Patients...
    Medical condition: Huntington's Disease (HD)
    Disease: Version SOC Term Classification Code Term Level
    17.0 10010331 - Congenital, familial and genetic disorders 10070668 Huntington's disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed) GB (Completed) CZ (Completed) DE (Completed) PT (Completed) NL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2013-004139-62 Sponsor Protocol Number: CRAD001JES13 Start Date*: 2014-01-02
    Sponsor Name:Novartis Farmacéutica S. A.
    Full Title: A pilot open-label, phase II, single-arm study to evaluate the association of biomarkers of hormonal resistance and the mTOR pathway with the clinical efficacy of everolimus plus letrozole in the f...
    Medical condition: Estrogen receptor or progesterone receptor positive locally advanced or metastatic breast cancer in postmenopausal women
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-005634-59 Sponsor Protocol Number: TEA-001 Start Date*: 2015-04-29
    Sponsor Name:Aarhus University Hospital
    Full Title: Toll-like receptor 9 enhancement of antiviral immunity in chronic HIV-1 infection: a phase 1b/2a trial (TEACH)
    Medical condition: HIV
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004862 10073675 HIV infection CDC category unspecified LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2017-000116-42 Sponsor Protocol Number: BioVacSafe-QIV Start Date*: 2017-03-02
    Sponsor Name:Ghent University Hospital
    Full Title: A clinical study of biomarkers of innate and adaptive immune activation associated with symptoms and immune responses after administration of a single dose of a quadrivalent inactivated split virus...
    Medical condition: Healthy Volunteers - a quadrivalent inactivated split virus influenza vaccine
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004865 10046859 Vaccination LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2023-000018-16 Sponsor Protocol Number: OZA22/IM047-048 Start Date*: 2023-04-19
    Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA
    Full Title: Effect of ozanimod on meningeal inflammation and glial activation in Multiple Sclerosis: one year phase 4 experimental study
    Medical condition: Relapsing Multiple Sclerosis (relapsing-remitting, relapsing-progressive)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029205 - Nervous system disorders 10080700 Relapsing multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-004635-30 Sponsor Protocol Number: UCL-ONCO-06-004 Start Date*: 2008-11-20
    Sponsor Name:CENTRE DU CANCER - CLINIQUES UNIVERSITAIRES SAINT-LUC
    Full Title: A randomized multicentric phase II study of prolonged adjuvant Temozolomide or "stop and go" in glioblastoma patients : the PATSGO study.
    Medical condition: It is an open-label, randomised multicentric phase II study of prolonged adjuvant Temozolomide versus "stop and go" in glioblastoma patients. This study will include a total of 70 patients. The st...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 03:48:34 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA